Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis

Clinical Cancer Research

Volumn 13, Issue 1, 2007, Pages 90-101

  Savage, Kay ^a   Lambros, Maryou B K ^a   Robertson, David ^a   Jones, Robin L ^a   Jones, Chris ^a   Mackay, Alan ^a   James, Michelle ^a   Hornick, Jason L ^b   Pereira, Emilio M ^c   Milanezi, Fernanda ^d,e   Fletcher, Christopher D M ^b   Schmitt, Fernando C ^d   Ashworth, Alan ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Laboratory of Clinical Pathology Salomão and Zoppi   (Brazil)

^d University of Porto   (Portugal)

^e UNIVERSITY OF MINHO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAVEOLIN 1; PARAFFIN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROBLAST; FROZEN SECTION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING;

BREAST; BREAST NEOPLASMS; CARCINOMA; CAVEOLIN 1; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MICROSCOPY, FLUORESCENCE; MICROSCOPY, IMMUNOELECTRON; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33846288318     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1371     Document Type: Article

References (50)

1. Hnasko R, Lisanti MP. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003;3:445-64.
2. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005;288:0494-506.
3. Chen ST, Lin SY, Yeh KT, et al. Mutational, epigenetic, and expressional analyses of caveolin-1 gene in breast cancers. Int J Mol Med 2004;14:577-82.
4. Engelman JA, Zhang XL, Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 1999;448:221-30.
5. Hayashi K, Matsuda S, Machida K, et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001;61:2361-4.
6. Jones C, Mackay A, Grigoriadis A, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004;64:3037-45.
7. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002;161:1357-69.
8. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998;16:1391 -7.
9. Park SS, Kim JE, Kim YA, Kim YC, Kim SW. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 2005;47:625-30.
10. Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006;99:85-90.
11. Sagara Y, Mimori K, Yoshinaga K, et al. Clinical significance of caveolin-1, caveolin-2, and HER2/neu mRNA expression in human breast cancer. Br J Cancer 2004;91:959-65.
12. Van den Eynden GG, Van Laere SJ, Van derAuwera I, et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006;95:219-28.
13. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998;4:1873-80.
14. Zou W, McDaneld L, Smith LM. Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. Anticancer Res 2003;23:4581-6.
15. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2005;25:2273-84.
16. Hurlstone AF, Reid G, Reeves JR, et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 1999;18:1881-90.
17. Huang H, Reed CP, Mordi A, et al. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer 1999; 24:48-55.
18. Nishizuka S, Tamura G, Terashima M, Satodate R. Commonly deleted region on the long arm of chromosome 7 in differentiated adenocarcinoma of the stomach. Br J Cancer 1997;76:1567-71.
19. Han SY, Druck T, Huebner K. Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics 2003;81:105-7.
20. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest 2001;108:1553-61.
21. Razani B, Schlegel A, Lisanti MP. Caveolin proteins in signaling, oncogenic transformation, and muscular dystrophy. J Cell Sci 2000;113:2103-9.
22. Sotgia F, Williams TM, Schubert W, et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006;168:292-309.
23. Li T, Sotgia F, Vuolo MA, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor α-positive status. Am J Pathol 2006;168:1998-2013.
24. Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A 1999;96:12589-94.
25. Reis-Filho JS, Milanezi F, Silva P, Schmitt FC. Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract 2001;197:817-21.
26. Mohsin SK, Zhang M, Clark GM, Craig Allred D. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 2003;199:432-5.
27. Simpson PT, Gale T, Reis-Filho JS, et al. Distribution and significance of 14-3-3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol 2004;202:274-85.
28. Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004;64:4277-85.
29. Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 1999;4:233-7.
30. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001;58:811-4.
31. Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002;94:929-33.
32. Ito Y, Yoshida H, Nakano K, et al. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer 2002;86:912-6.
33. Suzuoki M, Miyamoto M, Kato K, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002;87:1140-4.
34. Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004;10:5988-97.
35. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
36. Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005; 29:347-53.
37. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
38. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
39. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas show EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridisation analysis. Breast Cancer Res 2005;7:R1028-35.
40. Robertson D, Monaghan P, Clarke C, Atherton AJ. An appraisal of low-temperature embedding by progressive lowering of temperature into Lowicryl HM20 for immunocytochemical studies. J Microsc 1992;168:85-100.
41. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006;19:999-1009.
42. Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86:398-408.
43. Bhargava R, Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005;18:1027-33.
44. Clarke CL, Sandle J, Parry SC, Reis-Filho JS, O'Hare MJ, Lakhani SR. Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype. J Pathol 2004;204:147-52.
45. Pike LJ. Growth factor receptors, lipid rafts, and caveolae: an evolving story. Biochim Biophys Acta 2005;1746:260-73.
46. Khan EM, Heidinger JM, Levy M, Lisanti MP, Ravid T, Goldkorn T. Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem 2006;281:14486-93.
47. Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 2004;23:6967-79.
48. Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci 2002;115:1331-40.
49. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4:499-515.
50. Pinto AE, Roque L, Rodrigues R, Andre S, Soares J. Frequent 7q gains in flow cytometric multiploid/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation. J Clin Pathol 2006;59:367-72.